Global Congress on Bladder Cancer 2018

Global Congress on Bladder Cancer 2018

  • Robotic cystectomy: what's the evidence?
    Peter Wiklund
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • What is the role of novel, non-IO agents in MIBC?
    Michiel van der Heijden
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Adjuvant RT after cystectomy: a good idea?
    Valérie Fonteyne
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Debate: TURBT should be a redundant treatment in patients with MIBC
    Jürgen Gschwend, Nicholas James
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Overcoming barriers to progress in NMIBC - Where are we in 2018 and where will we be in 5 years?
    Ashish Kamat
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Congress highlights 2018: what you need to remember according to the urologist
    Jacques Irani
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Congress highlights 2018: what you need to remember according to the clinical oncologist
    Nicholas James
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • What’s in the boiling pot of NMIBC - case discussion
    Marek Babjuk, Badrinath Konety, Luis Martínez-Piñeiro
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Novel endoscopic imaging
    Sia Daneshmand
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Role of IO in NMIBC
    Badrinath Konety
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • IO in advanced disease
    Petros Grivas
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Role of chemotherapy
    Ignacio Durán
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Variant histology: what pathology can tell you
    Eva Comperat
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Multidisciplinary case discussion on patients with rare disease characteristics
    Eva Comperat, Maria De Santis, Georgios Gakis, Peter Hoskin
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • Has the molecular subtype impact on patient outcomes?
    Francisco X. Real
    Global Congress on Bladder Cancer 2018
    20 Sep 2018
  • The perfect lymph node dissection
    Jürgen Gschwend
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Practical considerations: what every clinician should know about immuno-oncology
    Margitta Retz
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Perioperative chemotherapy in cisplatin "unfit" patients
    Maria De Santis
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Controlling symptoms in metastatic bladder cancer
    Sergio Bracarda
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Personalised RT
    Ananya Choudhury
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • UTUC - Adjuvant chemotherapy for all patients?
    Alison Birtle
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • How may diagnostic imaging influence the treatment of advanced bladder cancer?
    Nigel Cowan
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Case discussion: the role of local control in MIBC and oligometastatic disease
    Peter Hoskin, Jacques Irani
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Vision on the future - patient representative
    Caroline Raw
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Vision on the future - medical oncology
    Petros Grivas
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Vision on the future - radiation oncology
    Xavier Maldonado
    Global Congress on Bladder Cancer 2018
    21 Sep 2018
  • Vision on the future - urology
    María J. Ribal
    Global Congress on Bladder Cancer 2018
    21 Sep 2018

We are sorry, but your browser is out of date.

An additional plug-in or an upgrade of your browser is required to play this video.